Hospitals

Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia

Friday, September 18, 2020 - 6:00am

The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm versus 19.3% in the placebo arm.

Key Points: 
  • The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm versus 19.3% in the placebo arm.
  • Actemra is currently being investigated as a potential treatment for COVID-19 associated pneumonia, including in combination with an anti-viral in the Phase III REMDACTA clinical trial.
  • Results from the Phase III COVACTA trial in patients with severe COVID-19 associated pneumonia were released in July.
  • EMPACTA (Evaluating Minority Patients with Actemra) is a Phase III, randomized, double-blind, placebo-controlled multicenter study (EMPACTA, NCT04372186) to evaluate the efficacy and safety of Actemra in the treatment of hospitalized COVID-19 associated pneumonia among patients that are often underrepresented in clinical trials.

Compass Health Celebrates Virtual Building Communities of Hope Gala by Honoring Client Stories on World Mental Health Day

Thursday, September 17, 2020 - 10:53pm

Compass Health , Northwest Washingtons behavioral healthcare leader, is proud to honor client stories and voices at its fourth-annual Building Communities of Hope Gala fundraiser, planned for October 10, 2020.

Key Points: 
  • Compass Health , Northwest Washingtons behavioral healthcare leader, is proud to honor client stories and voices at its fourth-annual Building Communities of Hope Gala fundraiser, planned for October 10, 2020.
  • The virtual event, which coincides with World Mental Health Day, will be streamed live on YouTube, and proceeds from the evening will support Compass Healths child, youth and family services.
  • Were thrilled to take this opportunity to truly amplify the voices of our clients in our first-ever virtual Gala.
  • The evening will feature an address by Sebastian followed by a video presentation led by Amanda, a Compass Health client and team member.

Thermal Scanner Market and Competitive Landscape & Pandemic Recovery Analysis 2020 - Technavio

Thursday, September 17, 2020 - 11:45pm

The research is classified into seven sections thermal scanner market landscape, market sizing, five force analysis, customer landscape, geographic landscape, drivers, challenges, and trends, and vendor landscape and analysis.

Key Points: 
  • The research is classified into seven sections thermal scanner market landscape, market sizing, five force analysis, customer landscape, geographic landscape, drivers, challenges, and trends, and vendor landscape and analysis.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    Thermal Scanner Vendors: Identify key vendors of the thermal scanner market, including company-revenue, market presence, influence-index, vendor-classification, and market positioning.
  • Thermal Scanner Region Growth: Find out the highest and slowest growth of regions for thermal scanner market.
  • Thermal Scanner Market Valuations: Find out the global market size for thermal scanner in 2019 and how the market will advance from 2020 to 2024.

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

Thursday, September 17, 2020 - 9:01pm

MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.

Key Points: 
  • MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.
  • The Phase 1b portion is an open-label dose escalation study which is evaluating doses up to 75 mg of KZR-616 across 6 cohorts, which has completed enrollment.
  • The Phase 2 portion of the MISSION study evaluating KZR-616 in patients with LN is currently enrolling.
  • Data generated from Phase 1a and 1b trials provide evidence that KZR-616 exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.

Outset Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Thursday, September 17, 2020 - 9:01pm

Outset Medical, Inc. (Nasdaq: OM) (Outset) today announced the closing of its initial public offering of 10,293,777 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,342,666 additional shares of common stock, at the initial public offering price of $27.00 per share.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (Outset) today announced the closing of its initial public offering of 10,293,777 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,342,666 additional shares of common stock, at the initial public offering price of $27.00 per share.
  • The gross proceeds to Outset, before deducting underwriting discounts and commissions and offering expenses, were approximately $277.9 million.
  • The shares began trading on The Nasdaq Global Select Market on September 15, 2020, under the symbol "OM."
  • Outset Medical, Inc. is a rapidly growing medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.

Henry Schein Opens Customer Assistance Hotline in Response to Hurricane Sally

Thursday, September 17, 2020 - 8:19pm

Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers along the Gulf Coast that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by Hurricane Sally.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers along the Gulf Coast that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by Hurricane Sally.
  • As Hurricane Sally makes landfall along the Gulf Coast, Team Schein stands ready to support the people and communities in the storms path, said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.
  • Dentists and physicians can rely on us to be a partner during difficult times, and we encourage our customers to call the Henry Schein Customer Assistance Hotline for assistance with recovery and rebuilding efforts.
  • The Henry Schein Customer Assistance Hotline remains open throughout the year to help practitioners during their preparation and recovery from disasters.

HealthShare Symposium 2020 Special Event, presented by Healthgrades, Encouraged Attendees to Turn Recent Challenges into Opportunities Within the Healthcare Ecosystem

Thursday, September 17, 2020 - 7:00pm

To that end, Healthgrades introduced Hg Mercury , healthcares only enterprise-wide intelligent engagement platform for accelerating health system growth.

Key Points: 
  • To that end, Healthgrades introduced Hg Mercury , healthcares only enterprise-wide intelligent engagement platform for accelerating health system growth.
  • With the Hg Mercury platform, health system leaders gain best next action insights that pinpoint market opportunities and guide hyper-targeted and personalized engagement.
  • The HealthShare Symposium 2020 Special Event enabled attendees to initiate an important conversation around reimagining the future and also reinforce Healthgrades leadership in the industry.
  • As described in the HealthShare Symposium 2020 Special Event Executive Summary, which was released today, hospital executives explored four key themes - resiliency, humanity, optimism, and opportunity - and how unprecedented challenges led to incredible progress within the healthcare ecosystem.

OncLive® Names the 2020 Class of Giants of Cancer Care®

Thursday, September 17, 2020 - 6:27pm

OncLive, the nations leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care class of inductees.

Key Points: 
  • OncLive, the nations leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care class of inductees.
  • The members of the 2020 class of Giants of Cancer Care are oncology legends who have made remarkable differences in the cancer care landscape, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of OncLive.
  • This years Giants of Cancer Care inductees by award category are:
    Breast Cancer Martine J. Piccart, M.D., Ph.D., Universit Libre de Bruxelles and Jules Bordet Institute.
  • Out of 818 nominations, only 15 oncologists were selected to the prestigious 2020 class of Giants of Cancer Care.

National Association of Specialty Pharmacy Names ParcelShield ‘Strategic Partner of the Year’

Thursday, September 17, 2020 - 5:51pm

ParcelShield , a healthcare technology company that develops high-performance parcel management solutions for specialty pharmacies, today announced that it has received the Strategic Partner of the Year Award from the National Association of Specialty Pharmacy (NASP).

Key Points: 
  • ParcelShield , a healthcare technology company that develops high-performance parcel management solutions for specialty pharmacies, today announced that it has received the Strategic Partner of the Year Award from the National Association of Specialty Pharmacy (NASP).
  • On behalf of the NASP, we are thrilled to present ParcelShield with the very first NASP Strategic Partner of the Year Award, said Sheila M. Arquette, RPH, President and CEO of NASP.
  • Its quite an honor to receive this first annual award from the association, said Guillermo Sollberger, CEO of ParcelShield.
  • The Specialty Partner of the Year award is given to the individual or company who has made a sustained contribution to the Specialty Pharmacy industry.

Anthem Blue Cross and Blue Shield Nevada More Than Doubled the Number of Members Receiving Whole-Person Treatment for Opioid Use Disorder

Thursday, September 17, 2020 - 4:30pm

Anthem Blue Cross and Blue Shield Nevada more than the doubled the number of health plan members receiving whole-person therapies, which are believed to produce better outcomes for opioid use disorder.

Key Points: 
  • Anthem Blue Cross and Blue Shield Nevada more than the doubled the number of health plan members receiving whole-person therapies, which are believed to produce better outcomes for opioid use disorder.
  • Anthem met this goal by successfully boosting the combined percentage of employer-based, individual and Medicaid health plan members with opioid use disorder who were receiving both therapies.
  • Anthem Blue Cross and Blue Shield Nevada helps improve health care access and quality for more than 600,000 Nevadans by developing innovative care management programs and services.
  • Anthem Blue Cross and Blue Shield is the trade name of Community Care health Plan of Nevada, Inc., an independent licensee of the Blue Cross and Blue Shield Association.